Evidence map›Paper›PMID 25545018›Full record

ArticleRedox report : communications in free radical research2015

Paliperidone regulates intracellular redox system in rat brain: Role of purine mechanism.

Kadir Demirci, Ramazan Özçankaya, H Ramazan Yilmaz, Ayşe Yiğit, Abdülhadi Cihangir Uğuz, Kadir Karakuş, Arif Demirdaş, Abdullah Akpınar

Open access · bronzeAbstract read
In one paragraph

Article in Redox report : communications in free radical research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Kadir Demirci
Ramazan Özçankaya
H Ramazan Yilmaz
Ayşe Yiğit
Abdülhadi Cihangir Uğuz
Kadir Karakuş
Arif Demirdaş
Abdullah Akpınar
Süleyman Demirel University · TRIsparta University of Applied Sciences · TRMevlana University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe treatment of schizophrenia is multifactorial, with antipsychotic medications comprising a major part of treatment. Paliperidone is a newly commercialized antipsychotic whose formulation includes the principal active metabolite risperidone, 9-hydroxyrisperidone. Ever since the relationship between schizophrenia and oxidative stress was first demonstrated, many studies have been conducted in order to probe the potential protective effects of antipsychotic drugs on the oxidant-antioxidant system and lipid peroxidation. The basic aim of this study is to determine the effects of the newly marketed drug paliperidone on the activities of the enzymes adenosine deaminase (ADA), xanthine oxidase (XO), superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px) as well as on malondialdehyde (MDA) and nitric oxide (NO) levels in rat brain tissues.

methodsTwenty male Sprague-Dawley rats were used for the study, which were divided into two equal groups. The first was the control group (n = 10) and the second was the paliperidone group (n = 10). Saline was administered once daily for 14 days in the control group. In the paliperidone group, paliperidone was administered once daily with a dose of 1 mg/kg for 14 days. All rats were sacrificed at the end of the fourteenth day. Brain samples were collected and then analyzed.

resultsOur results demonstrated that paliperidone significantly decreased the activities of ADA (P = 0.015), XO (P = 0.0001), and CAT (P = 0.004) while insignificantly increasing the activity of SOD (P = 0.49), MDA (P = 0.71), and NO (P = 0.26) levels in rat brain tissues. In addition, paliperidone insignificantly decreased the activity of GSH-Px (P = 0.30) compared to the control group in rat brain tissues. DISCUSSION: In conclusion, the data obtained in this study suggest that paliperidone can positively alter antioxidant status and, accordingly, can offer positive outcomes in the treatment of schizophrenia by reducing activity in the enzymes ADA and XO, which are associated with purine metabolism. We believe that such a comprehensive approach used with other antipsychotic drugs warrants further study.

Indexed as

Adenosine DeaminaseAnimalsAntipsychotic AgentsBrainBrain ChemistryCatalaseGlutathione PeroxidaseLipid PeroxidationMaleMalondialdehydeMembrane ProteinsNerve Tissue ProteinsNitric OxideOxidation-ReductionPaliperidone PalmitatePurinesAda protein, ratAdenosine DeaminaseAntipsychotic AgentsCatalaseGlutathione PeroxidaseMalondialdehydeMembrane ProteinsNerve Tissue ProteinsNitric OxidePaliperidone PalmitatePurinesSuperoxide DismutaseXanthine OxidaseAdenosine deaminaseCatalaseGlutathione peroxidaseMalondialdehydeNitric oxidePaliperidoneSuperoxide dismutaseXanthine oxidase

Identifiers

PMID25545018
PMCPMC6837464
OpenAlexW2065222090

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.